Collaboration, License, and Other Agreements - North America - General Information (Details) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2023
USD ($)
item
|
Mar. 31, 2022
USD ($)
|
|
Collaboration, License, Promotion and Other Commercial Agreements | ||
Research and development expense | $ 12,847 | $ 10,822 |
AbbVie Plc | ||
Collaboration, License, Promotion and Other Commercial Agreements | ||
Remaining commercial-period performance obligations | item | 3 | |
Cost sharing amount, reduction to research and development | $ 3,000 | 2,400 |
Collaborative arrangement, percentage of obligation of development costs incurred | 50.00% | |
Percentage of net profit from commercialization (as a percent) | 50.00% | |
Percentage of net loss from commercialization (as a percent) | 50.00% | |
North America | AbbVie Plc | ||
Collaboration, License, Promotion and Other Commercial Agreements | ||
Research and development expense | $ 1,300 | $ 1,700 |